Highly cell permeable purine compound that acts as a selective and ATP-competitive inhibitor of CDKs (IC50=6.6µM, 0.41µM, 5.5µM, 15µM and 3.9µM for CDK1/cyclin B, CDK2/cyclin A, CDK4/cyclin D, CDK5/p25 and CDK7/cyclin H) and displays anticancer properties. Causes cell cycle arrest at the G2/M phase and induces apoptosis by activating caspases and downregulating survivin.
Product Details
Alternative Name: | 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide |
|
Formula: | C23H30N6O2 |
|
MW: | 422.5 |
|
CAS: | 444723-13-1 |
|
Purity: | ≥95% (HPLC) |
|
Identity: | Determined by 1H-NMR and MS. |
|
Appearance: | White to off-white solid. |
|
Solubility: | Soluble in DMSO (10mg/ml). |
|
Shipping: | Ambient Temperature |
|
Long Term Storage: | +4°C |
|
Use/Stability: | Stock solutions are stable for up to 6 months when stored at -20°C. |
|
Handling: | Protect from light. Packaged under inert gas. |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation: M. Pennati, et al.; Mol. Cancer Ther.
4, 1328 (2005),
Abstract;